BRISBANE, AUSTRALIA: ResApp Health Limited (ASX:RAP), a number one digital well being firm developing smartphone applications for the diagnosis and administration of respiratory disease, has entered right into a binding scheme implementation deed with Pfizer Australia, under which it’s proposed that Pfizer will purchase 100% of the shares in ResApp Health for A$0.115 per share in money representing a complete fairness worth of roughly A$100 million.
Tony Keating, CEO and Managing Director of ResApp said, “We are excited by the prospect of this acquisition by Pfizer, a number one biopharmaceutical firm that shares our imaginative and prescient and perception that technology can assist transform healthcare and enhance patients’ lives. The proposed acquisition recognises the years of devoted work by the ResApp team to construct ResApp right into a chief in audio- based evaluation of respiratory health. We believe that the fabric premium and certainty of an all money consideration is an attractive outcome for our shareholders.”
Azure Capital Pty Ltd is acting as monetary adviser and DLA Piper as authorized adviser to ResApp.
“This proposed acquisition and evaluation collaboration add to our rising digital capabilities and bolster our efforts to pave a brand new period for digital health,” said Lidia Fonseca, Chief Digital and Technology Officer, Pfizer.
www.resapphealth.com.au